- Advertisement -
Home CURRENT AFFAIRS HEALTH Omicron’s Sub-Variant Hasn’t Increased Hospitalisations: Mandaviya On India’s Active Covid-19 Situation

Omicron’s Sub-Variant Hasn’t Increased Hospitalisations: Mandaviya On India’s Active Covid-19 Situation

In response to the increasing COVID cases in India, Union Health Minister Mansukh Mandaviya stated on Monday that there is no need for concern because the country’s circulating Omicron’s sub-variant has not caused a rise in hospitalisations.

The Minister emphasised the importance of always on guard.

Recently, there has been an increase in COVID cases in India, with daily fresh infections ranging from 2,994 on April 1 to 3,824 on April 2 to 3,641 on April 3.

In the past 24 hours, 1,800 individuals have recovered from the disease, bringing the nation’s total to 4,41,75,135.

“We need to remain alert but there is no need to worry. Currently, the sub-variant of Omicron which is circulating in the country hasn’t increased hospitalisations,” Mr Mandaviya s

Presently 20,219 active cases in the nation

In response to the nationwide spike in cases over the past week, the Ministry of Health and Family Welfare has released updated Covid-19 guidelines.

“Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease,” revised guidelines said.

“Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease,” revised guidelines said.

“Seek immediate medical attention if difficulty breathing, High-grade fever/ severe cough, particularly if lasting for more than 5 days. A low threshold is to be kept for those with any of the high-risk features,” guidelines discussed and prepared in January said.

Moreover, the guidelines state to “Consider Remdesivir for up to 5 days (200 mg IV on day 1 followed by 100 mg IV OD for the next 4 days) in moderate or severe diseases with high risk of progression.”

Also Read: OnePlus 11: Top variant with innovative features to launch in India, specs and all other details here

Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOKINSTAGRAM, and TWITTER

- Advertisement -